ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?

Irene M. Ghobrial, Alexander Keith Stewart

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A 51-year-old male was diagnosed with an IgA multiple myeloma (MM) after having back pain for several months. His bone marrow showed 30% involvement with plasma cells and his cytogenetics showed t(4:14). His beta2-microglobulin was 6.5 mg/dL at diagnosis and he had multiple lytic lesions, along with a creatinine of 2.3 mg/dL and significant anemia. Induction therapy with lenalidomide, bortezomib and dexamethasone was used, and he was able to achieve complete remission after 4 cycles of therapy. He then went on to receive high-dose chemotherapy with a single autologous stem cell transplant. He tolerated it well and now comes to discuss follow-up treatment plans. He wants to discuss maintenance therapy.

Original languageEnglish (US)
Pages (from-to)587-589
Number of pages3
JournalHematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
StatePublished - 2009
Externally publishedYes

Fingerprint

Multiple Myeloma
Guidelines
Therapeutics
Back Pain
Plasma Cells
Cytogenetics
Immunoglobulin A
Dexamethasone
Anemia
Creatinine
Stem Cells
Bone Marrow
Transplants
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{170f3c1839914b70bd040f46557bb855,
title = "ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?",
abstract = "A 51-year-old male was diagnosed with an IgA multiple myeloma (MM) after having back pain for several months. His bone marrow showed 30{\%} involvement with plasma cells and his cytogenetics showed t(4:14). His beta2-microglobulin was 6.5 mg/dL at diagnosis and he had multiple lytic lesions, along with a creatinine of 2.3 mg/dL and significant anemia. Induction therapy with lenalidomide, bortezomib and dexamethasone was used, and he was able to achieve complete remission after 4 cycles of therapy. He then went on to receive high-dose chemotherapy with a single autologous stem cell transplant. He tolerated it well and now comes to discuss follow-up treatment plans. He wants to discuss maintenance therapy.",
author = "Ghobrial, {Irene M.} and Stewart, {Alexander Keith}",
year = "2009",
language = "English (US)",
pages = "587--589",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",

}

TY - JOUR

T1 - ASH evidence-based guidelines

T2 - what is the role of maintenance therapy in the treatment of multiple myeloma?

AU - Ghobrial, Irene M.

AU - Stewart, Alexander Keith

PY - 2009

Y1 - 2009

N2 - A 51-year-old male was diagnosed with an IgA multiple myeloma (MM) after having back pain for several months. His bone marrow showed 30% involvement with plasma cells and his cytogenetics showed t(4:14). His beta2-microglobulin was 6.5 mg/dL at diagnosis and he had multiple lytic lesions, along with a creatinine of 2.3 mg/dL and significant anemia. Induction therapy with lenalidomide, bortezomib and dexamethasone was used, and he was able to achieve complete remission after 4 cycles of therapy. He then went on to receive high-dose chemotherapy with a single autologous stem cell transplant. He tolerated it well and now comes to discuss follow-up treatment plans. He wants to discuss maintenance therapy.

AB - A 51-year-old male was diagnosed with an IgA multiple myeloma (MM) after having back pain for several months. His bone marrow showed 30% involvement with plasma cells and his cytogenetics showed t(4:14). His beta2-microglobulin was 6.5 mg/dL at diagnosis and he had multiple lytic lesions, along with a creatinine of 2.3 mg/dL and significant anemia. Induction therapy with lenalidomide, bortezomib and dexamethasone was used, and he was able to achieve complete remission after 4 cycles of therapy. He then went on to receive high-dose chemotherapy with a single autologous stem cell transplant. He tolerated it well and now comes to discuss follow-up treatment plans. He wants to discuss maintenance therapy.

UR - http://www.scopus.com/inward/record.url?scp=77949437592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949437592&partnerID=8YFLogxK

M3 - Article

C2 - 20008243

AN - SCOPUS:77949437592

SP - 587

EP - 589

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

ER -